VANCOUVER, July 20 /CNW/ - Protox(TM) Therapeutics Inc. (TSX-V:PRX) today
announced that it has acquired a Phase II clinical stage program for the
treatment of cancer from Neurocrine Biosciences Inc. and the United States
Public Health Service (PHS). The targeted therapeutic toxin PRX321, formerly
known as NBI-3001, has received both Fast Track Designation and Orphan Drug
Status from the U.S. Food and Drug Administration (FDA) for primary brain
tumors. Fast Track Designation enables expedited review by the FDA of products
that are in clinical development and Orphan Drug Status provides a number of
benefits including seven years of market exclusivity.
